Q2 2025 Avanos Medical Inc Earnings Call Transcript
Key Points
- Avanos Medical Inc (AVNS) delivered strong second-quarter results with net sales of $175 million, reflecting a 2% organic sales growth compared to the previous year.
- The Specialty Nutrition Systems portfolio grew 5% organically, reaffirming Avanos Medical Inc (AVNS)'s leading position in enteral feeding.
- The Radiofrequency Ablation (RFA) business posted near 14% growth, driven by increased generator sales and higher procedure volumes.
- Avanos Medical Inc (AVNS) successfully closed the sale of its Hyaluronic Acid product line, aligning with its transformation strategy to focus on core sectors.
- The company maintained a strong balance sheet with $90 million in cash and $105 million in debt, providing strategic flexibility.
- Avanos Medical Inc (AVNS) recorded a non-cash impairment charge of $77 million in the Pain Management and Recovery unit due to market capitalization pressures.
- The Surgical Pain business experienced a decline, impacted by delays in implementing reimbursement decisions under the NOPAIN Act.
- The Game Ready portfolio reported slightly lower revenues compared to the previous year, indicating challenges in market performance.
- Free cash flow for the quarter was negative $4 million, influenced by tax payment timings and higher capital expenditures.
- The company faces ongoing challenges from tariffs, with $50 million in estimated incremental tariff-related manufacturing costs for the year.
Good morning, ladies and gentlemen, and welcome to the Avanos second-quarter 2025 earnings conference call. (Operator Instructions) I would now like to turn the conference over to Scott Galovan, Chief Financial Officer. Please go ahead, sir.
Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos 2025 second-quarter earnings conference call.
Presenting today will be Dave Pacitti, CEO, who will kick off the call by sharing a few leadership updates. Dave will then provide a high-level overview of our second-quarter results before turning it over to Jason Pickett, who has been serving as our Interim CFO. Jason will share additional details on these topics, provide an overview of our financial results, and 2025 assumptions inclusive of the impact of tariffs. We will finish the call with Q&A. A presentation of today's call is available on the Investors section of our website, avanos.com.
As a reminder, our comments today
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
